Recent News

• 11.19.2025 - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
• 11.13.2025 - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
• 11.11.2025 - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
• 10.13.2025 - Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Recent Filings

• 11.19.2025 - 8-K Current report
• 11.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.17.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report
• 11.12.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 11.10.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 11.07.2025 - DEF 14A Other definitive proxy statements